[Comment] Olaparib and ovarian cancer—overall survival outcomes

Health-care providers are increasingly using targeted therapies and personalised medicine to treat patients with cancer. In ovarian cancer, tumours with BRCA gene mutations are being targeted by these treatments. BRCA1 and BRCA2 mutations are associated with 10–15% of all ovarian cancers, but with the addition of somatic mutations, about 50% of high-grade serous tumours (the commonest ovarian cancer subtype) will have some form of mutation.1 Repairing DNA defects is a common natural event and if not achievable, cellular death occurs.

http://ift.tt/2f6NLiG